From the Food and Drug Administration.
S L
SL
Nightingale
D000995:Antitubercular Agents / Q000627:therapeutic use*; D001782:Blood Donors; D017277:Drug Approval; D004338:Drug Combinations; D055590:Electromagnetic Phenomena; D004868:Equipment Failure; D004864:Equipment and Supplies; D015658:HIV Infections / Q000276:immunology*; D018023:HIV Seronegativity / Q000235:genetics; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D011718:Pyrazinamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D014910:Wheelchairs
D000995:Antitubercular Agents; D004338:Drug Combinations; C087181:isoniazid, pyrazinamide, rifampin drug combination; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin